Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

cancer ("NSCLC") are on track to initiate in the third quarter of 2010, the second half of 2010 and early 2011, respectively."

Recent Business Highlights:

OGX-011

    -   The European Medicines Agency confirmed that they are in overall
        agreement with our Phase III development plan for OGX-011 in patients
        with CRPC.
    -   Two peer-reviewed manuscripts were published that further explain the
        biological function of clusterin, its role in promoting tumor
        resistance to cancer treatment, and the role of an inhibitor of
        clusterin such as OGX-011, to enhance the effectiveness of cancer
        therapies. One of the co-authors to these manuscripts, Dr. Martin
        Gleave, is also the Company's Chief Scientific Advisor.

OGX-427

    -   Grant funding was secured for a randomized, investigator-sponsored
        Phase II trial of OGX-427 when administered as a monotherapy to
        patients with CRPC.
    -   Two peer-reviewed manuscripts were published that provide further
        insight into the mechanism of action of heat shock protein 27
        (Hsp27). OGX-427 is designed to reduce levels of Hsp27.
    -   Final results from a Phase 1 study involving OGX-427 will be
        presented as part of the Scientific Program in a General Poster
        Session with discussion at the ASCO 2010 Annual Meeting. These final
        data, including results combining OGX-427 with docetaxel, will update
        preliminary data that was featured in an oral presentation at the
        ASCO 2009 meeting.

Corporate Highlights

    -   Dr. Jack Goldstein and Ms. H. Stewart Parker were appointed to the
        board of directors. Dr. Goldstein joins the board as chairman. In
        addition, Dr. Martin Mattingly has agreed to stand for election at
        the Company's upcoming
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... spotlight on the,ever-growing field of life sciences, Larta Institute,s ... in the midst of the dark backdrop of the,current ... to,focus on brilliant entrepreneurs in the life sciences, even ... years, through good,economic times and bad, the passion and ...
... 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced ... & Renshaw 5th Annual Global Healthcare Conference to be ... in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of Access ... 3:10 pm local time, 9:10 am Eastern time and ...
... May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... has,received a letter of approval from the ... for its Clinical Trial Application (CTA),to begin ... administration of,REOLYSIN(R) in combination with paclitaxel and ...
Cached Biology Technology:Betting on Change - The Venture Forum in 2008 2Betting on Change - The Venture Forum in 2008 3Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... New knowledge points to the fact that a genetically ... skin barrier, plays a decisive role in the origin ... 3000 school-children scientists of the Helmholtz Zentrum Mnchen and ... the German population carry variations of the filaggrin gene, ...
... (MS), neuroradiologists and neurologists of the University hospitals of ... tissue damage, most of which had remained unrecognized up ... medium, Gadofluorine M, in magnetic resonance imaging. The scientists ... the renowned medical journal Brain . ...
... , Now that Olympia is approaching, the Chinese authorities ... large cities with different measures. For example, the car ... ordered not to use 70 percent of all company ... even or odd days - in accordance with their ...
Cached Biology News:When our protective armor shows weakness 2Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2GKSS membranes reduce air pollution in Beijing 2
... host strains are K-12 derivatives that have ... and glutathione reductase (gor) genes, which greatly ... Studies have shown that expression in Origami(DE3) ... another host even though overall expression levels ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: